BOEHRINGER INGELHEIM CORP. INTERIM PRESIDENT IS WERNER GERSTENBERG,
Executive Summary
BOEHRINGER INGELHEIM CORP. INTERIM PRESIDENT IS WERNER GERSTENBERG, who is overseeing day-to-day operations while the firm searches for a permanent replacement for former President and CEO Digby Barrios, who left on June 22, the company said. Gerstenberg, who is corporate exec VP and chief financial officer, took over the topside position after the abrupt departure of Barrios. Senior VP James Ueberroth also departed the firm on June 22. Boehringer Ingelheim's terse announcement of the changes said only that Barrios left the firm for "philosophical reasons" about the company's "strategic direction." The firm offered no explanation for Ueberroth's departure. The sudden management upheaval comes after one of the senior executive officers recently accepted an elected position with one of the major trade associations in the drug industry. Boehringer Ingelheim has "initiated immediate steps to select a successor," the company said, but is not using an executive search firm to locate a replacement. Concerning his departure, Barrios said that he and the company are negotiating a settlement. Ueberroth was unavailable for comment. Barrios, a former Squibb group VP, joined Boehringer Ingelheim Pharmaceuticals in 1983 as an exec VP. In 1988, he succeeded Harvey Sadow as B-I Corp. president and CEO ("The Pink Sheet" March 21, 1988, T&G-6). Gerstenberg, a native of Germany, also joined Boehringer Ingelheim Pharmaceuticals in 1983 as a senior VP. He was initially employed by Boehringer Ingelheim in Germany in 1968.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth